H-LFLEPTQADIALLK-OH

Ref. 3D-PP46362

Informations sur le produit

• Nom: H-LFLEPTQADIALLK-OH
• Synonymes: NH2-Leu-Phe-Leu-Glu-Pro-Thr-Gln-Ala-Asp-Ile-Ala-Leu-Leu-Lys-OH

Description

Peptide H-LFLEPTQADIALLK-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-LFLEPTQADIALLK-OH include the following: Development of an LC-MS/MS proposed candidate reference method for the standardization of analytical methods to measure lipoprotein (a) SM Marcovina, N Clouet-Foraison - Clinical , 2021 - academic.oup.comhttps://academic.oup.com/clinchem/article-abstract/67/3/490/6124783 Kringle Iv-2 Independent Quantitation Of Serum Apo (A) By Mass Spectrometry R Ruhaak , F Romijn, N Smit, M Pieterse - , 2019 - atherosclerosis-journal.comhttps://www.atherosclerosis-journal.com/article/S0021-9150(19)30783-X/abstract Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects R Nandakumar, A Matveyenko, T Thomas - Journal of Lipid , 2018 - ASBMBhttps://www.jlr.org/article/S0022-2275(20)34164-X/fulltext An LC-MS-based designated comparison method with similar performance to the Lp (a) reference measurement procedure to guide molar Lp (a) standardization NM Diederiks, LR Ruhaak , FP Romijn, MM Pieterse - Clinical Proteomics, 2024 - Springerhttps://link.springer.com/article/10.1186/s12014-023-09446-5 Romi n NM Diederiks, LR Ruhaak - , Smit, NPM, & , 2024 - scholarlypublications https://scholarlypublications.universiteitleiden.nl/access/item%3A3720868/download Standardization of Analytical Methods for the Measurement of Lipoprotein (a): Bridging Past and Future Initiatives N Clouet-Foraison, T Vaisar, SM Marcovina - Lipoprotein (a), 2023 - Springerhttps://link.springer.com/chapter/10.1007/978-3-031-24575-6_19 Simultaneous quantitation and size characterization of apolipoprotein (a) by ultra-performance liquid chromatography/mass spectrometry ME Lassman, TM McLaughlin, H Zhou - Rapid , 2014 - Wiley Online Libraryhttps://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/rcm.6883 Effects of Mipomersen, an apoB100 antisense, on Lp (a) metabolism in healthy subjects. MD Reyes-Soffer, G Reyes-Soffer - researchgate.nethttps://www.researchgate.net/profile/Rajasekhar-Ramakrishnan-2/publication/328134259_Effects_of_Mipomersen_an_apoB100_antisense_on_Lpa_metabolism_in_healthy_subjects/links/5f87c27a92851c14bcc8dad2/Effects-of-Mipomersen-an-apoB100-antisense-on-Lpa-metabolism-in-healthy-subjects.pdf Relating Lipoprotein (a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests M Szarek , E Reijnders , JW Jukema , DL Bhatt - Circulation, 2024 - Am Heart Assochttps://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.123.066398 Rei finders, E., ukema M Szarek - W., Bhatt, DL, Bittner, V.., Diaz, R , 2024 - scholarlypublications https://scholarlypublications.universiteitleiden.nl/access/item%3A3721114/download Development of an LC-MRM-MS-based candidate reference measurement procedure for standardization of serum apolipoprotein (a) tests LR Ruhaak , FP Romijn, I Begcevic Brkovic - Clinical , 2023 - academic.oup.comhttps://academic.oup.com/clinchem/article-abstract/69/3/251/6987871 Quantifying apolipoprotein (a) in the era of proteoforms and precision medicine LR Ruhaak , CM Cobbaert - Clinica Chimica Acta, 2020 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0009898120304927 Romi n LR Ruhaak - FPHTM, Brko ic, IB, Kuklen ik, Z , 2023 - scholarlypublications https://scholarlypublications.universiteitleiden.nl/access/item%3A3618803/download Apolipoprotein (a) kinetics in statin-treated patients with elevated plasma lipoprotein (a) concentration L Ma, DC Chan , EMM Ooi , SM Marcovina - The Journal of , 2019 - academic.oup.comhttps://academic.oup.com/jcem/article-abstract/104/12/6247/5544514 Studies of the metabolism of lipoprotein (a) in humans L Ma - 2020 - research-repository.uwa.edu.auhttps://research-repository.uwa.edu.au/en/publications/studies-of-the-metabolism-of-lipoproteina-in-humans Commutability assessment of candidate reference materials for lipoprotein (a) by comparison of a MS-based candidate reference measurement procedure with I Dikaios, H Althaus, E Angles-Cano - Clinical , 2023 - academic.oup.comhttps://academic.oup.com/clinchem/article-abstract/69/3/262/6987870 Measurement of apo (a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry H Zhou, J Castro-Perez, ME Lassman - Rapid , 2013 - Wiley Online Libraryhttps://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/rcm.6572 PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein (a) particles in statin-treated patients with elevated lipoprotein (a) GF Watts, DC Chan , J Pang , L Ma, Q Ying , S Aggarwal - Metabolism, 2020 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0026049520300858 C. Stefanutti, MD, PhD*, L. Pisciotta, MD, E. Favari, PhD, S. Di Giacomo, MD, PhD, F. Vacondio, PhD, MG Zenti, MD, C. Morozzi, MD, D. Berretti, MD, D. Mesce GF Watts - 2023 - core.ac.ukhttps://core.ac.uk/download/pdf/326720452.pdf Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans G Reyes-Soffer, M Pavlyha, C Ngai, T Thomas - Circulation, 2017 - Am Heart Assochttps://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.116.025253 Unmet Need For Secondary Prevention In Individuals With Hyperlipoproteinemia (A): The Copenhagen General Population Study CM Madsen, PR Kamstrup, A Varbo - , 2019 - atherosclerosis-journal.comhttps://www.atherosclerosis-journal.com/article/S0021-9150(19)30784-1/abstract Lipoprotein (a) concentration, genetic variants, apo (a) isoform size, and cellular cholesterol efflux in patients with elevated Lp (a) and coronary heart disease C Stefanutti, L Pisciotta , E Favari , S Di Giacomo - Journal of Clinical , 2020 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1933287420300830 PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein (a) Ex Vivo AEB by Alirocumab - 2016 - researchgate.nethttps://www.researchgate.net/profile/M-Croyal/publication/309597466_PCSK9_Modulates_the_Secretion_But_Not_the_Cellular_Uptake_of_Lipoproteina_Ex_Vivo/links/586a8a1108ae329d6211147c/PCSK9-Modulates-the-Secretion-But-Not-the-Cellular-Uptake-of-Lipoproteina-Ex-Vivo.pdf Translational Sciences A Thedrez, B Sjouke, M Passard - Thromb Vasc Biol, 2016 - researchgate.nethttps://www.researchgate.net/profile/M-Croyal/publication/322112535_Homozygous_Familial_Hypercholesterolemia_Patients_With_Identical_Mutations_Variably_Express_the_LDLR_Low-Density_Lipoprotein_Receptor_Implications_for_the_Efficacy_of_Evolocumab/links/5cfa27a2299bf13a384382be/Homozygous-Familial-Hypercholesterolemia-Patients-With-Identical-Mutations-Variably-Express-the-LDLR-Low-Density-Lipoprotein-Receptor-Implications-for-the-Efficacy-of-Evolocumab.pdf Lipoprotein (A) And Risk Of Ischemic Stroke In The General Population A Langsted, BG Nordestgaard - , 2019 - atherosclerosis-journal.comhttps://www.atherosclerosis-journal.com/article/S0021-9150(19)30782-8/abstract

• Marque: Biosynth